Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

Ozempic (semaglutide) and Victoza (liraglutide) are prescription drugs used to treat type 2 diabetes and reduce the risk of cardiovascular problems. Both drugs come as an injection. Ozempic and ...

Bernstein said Novo Nordisk’s (NVO) recently released SOUL ... SOUL results were more in line with Novo’s LEADER study of Victoza, also known as liraglutide, which showed a roughly 13% ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Novo Nordisk remains a sell due to increased competition ... the latest announcement from Hims & Hers competes directly with the Novo drugs Victoza and Saxenda, which were labeled as close to ...

which Novo Nordisk sells under the brand names Saxenda and Victoza. In the liraglutide research, data from a midstage trial found that the drug may slow the progression of Alzheimer's disease by ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report ... period for Novo’s GLP-1 predecessor Victoza—contributed to Novo’s overall third ...

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...

1 Day NVO 1.88% DJIA 0.68% S&P 500 -0.03% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...